

Calibr-Skaggs Drug Accelerator

Category:

Best Incubator, Accelerator, Equity

Program/Fund Name:

Calibr-Skaggs Drug Accelerator

Corporate Name:

Calibr-Skaggs Institute for Innovative Medicines

Date of Creation:

2012-06-01

Indications:

Any. Our goal is to make innovative medicines that fulfill unmet medical needs, so we do not limit the indications that we pursue.

Indications that have reached clinical trials: Idiopathic pulmonary fibrosis, inflammatory bowel disease, malaria, tuberculosis, HIV, B-cell lymphomas, metastatic breast cancer, prostate cancer, B-cell-driven autoimmune diseases (rheumatoid arthritis, lupus, systemic sclerosis, and myositis), osteoarthritis, COVID-19, neurodegenerative diseases (Alzheimer's and Parkinson's), obesity and obesity-related diseases.

Other indications being pursued: Heart failure, Crohn's disease, pouchitis, vision loss (macular degeneration, persistent corneal epithelial defects), neglected tropical diseases, cryptosporidiosis, fibrotic conditions (lung, liver, skin, kidney), MASH, dengue, hepatitis B and C, neurological diseases, psychotic diseases, bladder cancer, and many more.

Therapeutic Areas:

As Calibr-Skaggs employs a systems-level approach to solve the most pressing health challenges, our work spans multiple therapeutic areas.

Our key disease areas include:

- Cancer: We are advancing a portfolio of novel therapies designed to treat a variety of cancers, including hematologic malignancies and solid tumors of the breast, lung, bladder and other organs. Many of these programs are powered by our proprietary technology platforms, such as switchable chimeric antigen receptor T cells (sCAR-T) and multivalent antibody therapeutics. Our deep investment in immuno-oncology, combined

with high-throughput screening capabilities, has enabled multiple programs to progress from concept to first-in-human clinical trials.

- Regenerative and aging-related diseases: We have developed a unique approach to coaxing a patient's own stem cells into regenerating new, healthy tissue. We are pursuing a strategy of developing small molecule drugs that work to control the fate of endogenous stem cells-those found within tissues-to repair tissue damage. These first-in-class regenerative medicines could globally address a range of chronic and aging-associated illnesses, like osteoarthritis, heart disease, lung disease, macular degeneration, inflammatory bowel disease (IBD) and much more.
- Neurological diseases: We pursue disease-modifying approaches by targeting key pathological mechanisms-such as neuroinflammation-that drive disorders including Alzheimer's, Parkinson's and various psychotic conditions. Our programs leverage advanced drug design and long-acting platforms to improve therapeutic outcomes and patient adherence.
- Inflammatory and metabolic diseases: Chronic inflammation is now recognized as a common driver across numerous diseases. By targeting these pathways, we are developing treatments for conditions such as chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDS) and IBD. Our pipeline includes innovative biologics and oral small molecules, as well as long-acting incretin-based therapies for obesity and related metabolic disorders-all supported by our proprietary technologies.
- Global health: We develop therapies for diseases disproportionately affecting low- and middle-income countries, including malaria and tuberculosis, while ensuring they are optimized for distribution to these patient populations. For example, we leverage our long-acting platform to optimize existing therapies to reduce dosing frequency and costs. We believe that advancing these treatments not only strengthens global health systems but also reinforces public health at home. Our work in this space is rooted in scientific rigor and global equity.

FUND & SERVICE File Document upload:

N/A

History of the development of the fund / Incubators:

The Calibr-Skaggs Institute for Innovative Medicines was founded as 'Calibr' in 2012 based on the principle that creating new medicines can be accelerated by pairing world-class biomedical research with state-of-the-art drug discovery and development capabilities. As a translational bridge between academia and industry, Calibr-Skaggs works with several academic, nonprofit and pharmaceutical industry partners to advance therapies, including the Gates Foundation and AbbVie.

Calibr officially became a division of Scripps Research in 2018 as a self-funded, translational research center to create a unique vision for Scripps Research as a world

leader in biomedical research that translates scientific discovery into medicines that impact patients. Its state-of-the-art infrastructure and translational capabilities help amplify the impact of discoveries made in Scripps Research laboratories, while interdisciplinary scientists also advance internally developed programs forward. The institute is central to Scripps Research's innovative funding strategies that provide a sustainable model for science and biomedical research and that amplifies investment in science and grows with success. In 2023, Calibr was renamed the Calibr-Skaggs Institute for Innovative Medicines in honor of transformational support from the Skaggs family through the ALSAM Foundation.

By leveraging its unique infrastructure, strategic partnerships and generous philanthropic support, 13 programs have been advanced into clinical development, and several are undergoing investigational new drug (IND)-enabling studies-an unprecedented accomplishment in the nonprofit world.

This success is enabled by the highly collaborative, interdisciplinary team at Calibr-Skaggs. As our focus is making improved drugs and securing clinical proof-of-concept, we have employed experts spanning drug screening, medicinal chemistry, protein chemistry, pharmacology, regulatory/clinical operations, clinical translation, and business development. Given our broad expertise identifying and developing small-molecule drugs, biologics and cell therapies and then advancing these therapies to the clinic, we can create therapeutic candidates for a range of indications.

Calibr-Skaggs established multiple platform technologies that accelerate drug discovery and development, including but not limited to:

- Advanced drug screening and target ID capabilities including:

- ReFRAME, the world's largest open-access drug repurposing library that saves up to \$15M and 18 months per project

- Launched in 2018 with funding from the Gates Foundation

- Initiated 6 clinical-stage programs

- 80 billion compound DNA-encoded screening library

- To find compounds for difficult-to-treat drug targets

- Long-acting platform that can extend efficacy of drugs for the intended patient population with improved safety and lower drug cost

- Includes prodrug, depot, peptide-stapling and antibody-fusion strategies

- Used for 4 clinical-stage programs

- Switchable chimeric antigen receptor T cell (sCAR-T) therapy platform

- Biologic \"switch\" controls sCAR-T cell activity, so switches can be rapidly developed for specific indications but used with the same cell therapy

- Used in 3 clinical-stage programs

Importantly, Calibr-Skaggs scientists have refined these workflows and others over time. This is why continuity is central to our model. At Calibr-Skaggs, scientific expertise is housed under one roof and spans countless disease areas-including those traditionally deprioritized by commercial drug developers. As key learnings from one

program feed into numerous others, our drug discovery and development engine churns faster, smarter and more effectively over time.

History of the development of the fund / Incubators:

Transformational medicines begin with radical ideas. Reversing the aging process. Turning cancer from a deadly disease into a chronic condition. Ridding the world of malaria. Many of these breakthroughs first spark in academic labs, where scientists push the boundaries of what's possible. Yet, for these ideas to reach patients, they must navigate the complex path to becoming real-world treatments.

Too often, they don't make it.

A metaphorical \"Valley of Death\" separates academia from the biopharmaceutical industry, where science stagnates between the lab bench and the clinic. There are countless reasons why this happens-funding limitations, lack of infrastructure or resources, academic researchers unfamiliar with the translational process, market incentives in an already-risky industry. But the end result is the same. Promising research is left to die on the vine, and patients with 'unmarketable' diseases remain underserved. Transformational medicines take decades to come to fruition when, with the right approach, they could emerge in just a few years.

What if we could change that?

Imagine an academic center that operates like a biotech, without the traditional constraints of investors or siloed pipelines. An efficient organization focused on continuity, where expertise is housed under one roof and spans countless disease areas (including those that don't traditionally offer a return on investment). A drug discovery and development engine that churns continually faster and faster, as key learnings from one program feed into numerous others.

Imagine a team of drug inventors fluent in both worlds-academia and industry-who can bridge the gap between radical ideas and real treatments. A group driven not by short-term returns, but by a singular mission: to bring transformational medicines to patients, faster.

Scientific progress depends on integration. Health and disease are deeply interconnected, and our approach to drug discovery and development approach must reflect that. This is just the beginning. The opportunity is vast. This is how we improve human health and impact global society.

This is Calibr-Skaggs.

The Calibr-Skaggs Institute for Innovative Medicines is a drug discovery and development engine built to fuel the next generation of transformational treatments. As

part of Scripps Research, our team bridges scientific discovery and translational medicine, ensuring bold ideas accelerate from the lab bench to the clinic. Our model is designed for speed and impact: we rigorously assess new opportunities, rapidly advancing the most promising discoveries and forging strategic partnerships to expand our reach. With a clinical-stage pipeline spanning numerous disease areas and therapeutic modalities-including those often overlooked by traditional market forces-our mission is clear: to deliver life-changing medicines to patients across the globe, efficiently and at scale.

HISTORY & FOCUS File Document upload:

N/A

How do you address your portfolio needs:

Calibr-Skaggs Institute operates as a nonprofit drug discovery engine embedded within Scripps Research, and maintains a diverse portfolio. With a focus on addressing unmet medical needs across a range of diseases-including rare conditions, neglected diseases, global health threats, and chronic illnesses-the institute employs a purpose-driven portfolio strategy to ensure therapeutic impact.

Calibr-Skaggs designs its portfolio to apply scientific innovation across therapeutic modalities and indications. Programs are selected for their ability to address high unmet needs while remaining feasible for development. To ensure the pipeline remains robust, Calibr-Skaggs balances programs across all development stages, from discovery to clinical trials. The portfolio also spans diverse modalities, including small molecules, biologics, and cell therapies, and integrates cutting-edge discovery platforms, high-throughput screening, and medicinal chemistry with clinical insight. Each program undergoes rigorous evaluation to identify therapies that are differentiated from existing options and have the potential to deliver transformative results.

A unique aspect of Calibr-Skaggs' portfolio is its commitment to global health. The institute actively develops therapies for diseases predominantly affecting low-and-middle-income countries. These programs, while not marketable, are supported through our evergreen funding model that balances global health efforts with market-driven programs. By working with nonprofit partners and licensing therapies with commercial potential to pharmaceutical companies, Calibr-Skaggs secures funding to sustain its global health initiatives.

Cycling in new, innovative programs is instrumental to our model. Although new programs often arise organically from ongoing drug development activities, new programs also emerge from discoveries made internally, at Scripps Research, or from external collaborations. Calibr-Skaggs hosts "New Program Review Meetings," where researchers can pitch ideas for new drug programs. These sessions involve leaders with

diverse expertise, enabling a swift assessment of a program's feasibility and potential impact. This ensures that promising science is responsibly advanced toward clinical development.

Calibr-Skaggs manages its portfolio by integrating perspectives from leadership across the institute. This is enabled by our flat organizational structure that promotes rapid decision-making and collaboration across traditionally siloed teams. For example, in weekly Project Review Meetings, leaders from all areas of drug development—including the CEO, Entrepreneur-in-Residence, and Chief Medical Officer—provide rapid feedback and make decisions for every program, even those in the earliest stages. This integrated approach ensures that time and resources are directed toward programs with a clear path forward and accelerates the progress of programs addressing high unmet needs.

Calibr-Skaggs exemplifies how a mission-driven, collaborative approach can address diverse portfolio needs while maintaining a focus on scientific opportunity and humanitarian impact. Its integration of academic innovation, cutting-edge technology, and strategic foresight positions it as a leader in transforming scientific discoveries to impact human health.

Impact / Metrics to measure Success:

Calibr-Skaggs is a nonprofit organization dedicated to accelerating the translation of cutting-edge discoveries into innovative medicines. Positioned uniquely between academia and industry, Calibr-Skaggs leverages the flexibility of an academic institution and the drug development infrastructure of pharmaceutical companies to open new horizons for medical discovery across various indications and modalities. This approach enables broad impact across medicine, allowing Calibr-Skaggs to explore radical, potentially paradigm-shifting therapies.

One metric of success is the number of programs that reach IND clearance or its international equivalents. To date, 13 programs from Calibr-Skaggs have achieved this milestone. Additionally, we measure success by the number of programs in late-stage development, which are undergoing IND-enabling studies. Currently, there are 3 programs at this stage, with several more expected to advance soon.

As an accelerator, Calibr-Skaggs also values metrics such as time to the clinic and improvement of internal processes and platforms that can accelerate drug discovery and development activities. Notable platform technologies that have led to clinical-stage candidates include the long-acting platform (4 clinical-stage programs), sCAR-T platform (3 clinical-stage programs), small molecule regenerative therapy platform (2 clinical-stage programs), and the ReFRAME drug screening library (6 clinical-stage programs). As a world-class drug repurposing platform, ReFRAME has its own metrics of success including number of compounds in library (>13,500), primary

data uploaded to reframed.org (113), cost-savings with ReFRAME (up to \$15M), and time saved with ReFRAME (up to 18 months). Leveraging platform technologies and streamlined internal processes, our clinical COVID-19 program went from initial screening hit to the clinic in 18 months. This is a prime example of how our experienced, collaborative team and the technologies they develop can accelerate drug programs.

As a nonprofit bridging the gap between academia and industry, collaborations that advance the translation of innovative therapies is another metric of success. While Calibr-Skaggs can accelerate development from discovery through phase 1, partners are instrumental in providing funding, expertise, and advancing therapies past phase 1. In addition to multiple academic collaborators, Calibr-Skaggs has established 18 partnerships with nonprofit organizations, such as the Gates Foundation, and 8 partnerships with industry, including AbbVie. These partnerships provide various levels of support in accelerating programs through preclinical development, with some partners licensing programs for clinical advancement. Calibr-Skaggs continues to maintain and seek new partnerships to ensure that the therapies developed reach patients as soon as possible.

For Calibr-Skaggs, success is ultimately determined by the development of drugs that transform patient treatment and improve their quality of life. For example, our switchable CAR-T therapy allows clinicians to control CAR-T activity and reduce incidence of life-threatening inflammatory side effects, which could improve safety of CAR-T therapies. Our long-acting malaria therapy could prevent malaria infections in people in low- and middle-income countries with fewer doses, reducing emergence of therapeutic resistance and potentially saving millions of lives. Additionally, our small molecule regenerative therapy delivered after myocardial infarction could revolutionize cardiology. If these or any of the transformational therapies in our pipeline are approved, the patient impact would be the ultimate success.

Why your model is innovative, \and/or how it will improve the human condition:

Founded in 2012, we are the engine that drives high-risk, high-reward science across the metaphorical valley of death-pairing world-class discovery at Scripps Research with deep translational expertise of Calibr-Skaggs. Our unique, self-sustaining approach allows us to rapidly translate discoveries into first-in-class and best-in-class medicines, even in areas often deprioritized by industry. In this short amount of time, we have advanced more than a dozen programs into clinical and preclinical stages.

This model, envisioned by Scripps Research and Calibr-Skaggs President and CEO Pete Schultz, accelerates scientific progress through a self-sustaining cycle:

- Foundational discoveries seed drug discovery
- Candidate medicines are developed and tested in-house

- Strategic alliances with biopharmaceutical partners and nonprofit foundations, including organizations like AbbVie and the Gates Foundation, help bring medicines to market
- Royalties are reinvested in new research

By seamlessly integrating curiosity-driven foundational research with a robust drug discovery pipeline within a single institute, we are addressing one of the major challenges facing scientific institutions-the funding of nonprofit research. Traditional federal funding mechanisms often fail to incentivize risk-taking and the commitment needed to tackle transformative research ideas, but rather, favor incremental progress in established fields. Philanthropic dollars are most often placed in endowments that prevent their full impact from being realized.

By turning scientific discoveries into new medicines, Calibr-Skaggs is not only impacting human health, but also creating a self-renewing revenue stream by partnering these medicines with pharma for further development. These licensing revenues are then reinvested into our research programs, ensuring a continuous stream of scientific breakthroughs and a strong pipeline of next-generation transformative medicines. This is a flywheel model where success begets success-as science is turned into new medical advances, we create more resources to further expand our impact and amplify our investment in the scientific and medical enterprise.

The innovative resources enabled by our model that can be applied across disease areas, expanding our impact beyond a single program. For example, learnings from a long-acting injectable therapy developed to reduce the number of doses for patients with psychiatric disease can be applied to improve access and limit resistance to a therapy that prevents malaria transmission in low-and-middle income countries. Continual reinvestment in existing therapeutic platforms makes our processes more efficient, while investment in innovative ideas can launch new therapeutic platforms that address critical unmet needs in medicine. Our investment in these innovative resources accelerates future drug development programs to get better therapies to patients, faster.

Please provide appropriate references (PubMed, Abstract, Website):

Abstract:

The Calibr-Skaggs Institute for Innovative Medicines at Scripps Research is a pioneering nonprofit translational research center dedicated to accelerating the development of new medicines. Founded in 2012, the institute leverages world-class biomedical research and state-of-the-art drug discovery and development capabilities to create therapeutic candidates for a wide range of indications, including oncology, regenerative medicine, neurological diseases, metabolic diseases, and infectious diseases. As a

translational bridge between academia and industry, Calibr-Skaggs collaborates with academic, nonprofit, and pharmaceutical industry partners to advance therapies and accelerate the drug development process. The institute's unique infrastructure, strategic partnerships, and generous philanthropic support have enabled it to achieve unprecedented accomplishments in the nonprofit world, including the advancement of 13 programs into clinical development and several undergoing investigational new drug (IND)-enabling studies. Advancing these programs from discovery to clinical application helps to enhance our pipeline, improving efficiency and speeding up the translation of new therapies to patients.

Website: <https://calibr.scripps.edu/>;

Website for ReFRAME, world's largest open-access drug repurposing library with associated data: <https://reframedb.org/>

Examples/Case Study

Drug development is historically slow, so Calibr-Skaggs scientists created the world's largest open-access drug repurposing library and database, ReFRAME (Repurposing, Focused Rescue, and Accelerated Medchem), to help accelerate drug development programs at Calibr-Skaggs and around the world. Since its launch in 2018, ReFRAME has proven its ability to significantly accelerate drug discovery, cutting costs by up to \$15 million and saving up to 18 months per project. This was demonstrated by the rapid development of CMX990 for SARS-CoV-2 at Calibr-Skaggs and repurposing rifabutin to tackle antimicrobial resistance by researchers at University of Southern California.

Our SARS-CoV-2 drug candidate, CMX990, began as a screening hit for molecules with moderate SARS-CoV-2 antiviral potency, but initial indications of the identified molecules were not antiviral. The 21 ReFRAME hits included emricasan, which is FDA approved to treat liver disease; VBY-825, which is being investigated to treat cancer; and dutacatib, which reached a Phase 1 trial for osteoporosis. After incorporating literature knowledge with structure-activity relationship (SAR) assessment, CMX990 was advanced from initial medicinal chemistry optimization to a Phase 1 clinical trial in 10 months (PMID: 38335279), indicating that ReFRAME truly can accelerate drug discovery efforts.

In collaboration with researchers at the University of Southern California, we used ReFRAME to identify existing therapies that could be used as therapies to combat antimicrobial resistance (AMR). This ReFRAME screen identified rifabutin, a therapy that prevents mycobacterium avium complex (MAC) disease in people with weakened immune systems, as a potential AMR therapy. While developing a novel compound would require time-consuming, expensive experiments to obtain IND clearance, repurposing rifabutin bypassed these experiments-saving an estimated \$10M before initiation of the phase 1 trial.

Sharpening our knives: what we learn from past and current drug development programs accelerates future programs. Calibr-Skaggs scientists are continually improving their skills and finding new ways to improve drug development. While we are always improving our standard internal workflows and learning how to run new screening assays and in vivo efficacy studies that extend the breadth of our expertise,

our ability to develop innovative strategies that accelerate drug development is exemplified by our platform technologies.

Our long-acting platform uses multiple strategies to extend the efficacy of drugs. For our long-acting GLP2 therapy to regenerate colonic epithelium in inflammatory bowel disease, we used our peptide stapling technology to stabilize the protein structure. This therapy completed a phase 1 clinical trial and is now progressing to two phase 2 trials: 1 to treat pouchitis after colon removal and another to treat environmental enteric dysfunction (EED) in people living in low- and middle-income countries. Experience developing and translating this therapy informed development of another peptide-stapled therapy that is initiating a phase 1 clinical trial to treat obesity and metabolic diseases. Similarly, we have 2 clinical-stage programs using prodrug and formulation strategies to extend the half-lives of existing HIV and malaria drugs. Knowledge gained during these processes has informed development of multiple therapies that would improve patient compliance and efficacy if long-acting therapies were available. This extensive pipeline includes therapies for HIV, malaria, HCV, HBV, Lyme disease, and psychiatric disease.

Innovations arising from our model also include the sCAR-T platform. First advanced to the clinic in 2019 (NCT04450069), 2 more therapies using the same platform technology were advanced to the clinic in 2025. The sCAR-T program is a cell therapy (CAR-T) that is activated with a biologic "switch," where activity of the CAR-T cells can be more precisely controlled by the physician. Since the initial B-cell lymphoma trial resulted in cures for 6 of 9 participants and greatly reduced the potentially deadly side effects of conventional CAR-T therapies. Building upon the existing sCAR-T infrastructure and the need to only develop new biologic switches, the 2 follow-up programs were accelerated to the clinic for solid tumors (NCT06878248) and autoimmune diseases (NCT06913608).

Calibr-Skaggs has also established a robust regenerative medicine pipeline based on innovative research from Scripps scientists. Scripps researchers have discovered novel targets in terminally differentiated cells that unlock stem cell-like behaviors such as proliferation. In collaboration with these researchers, Calibr-Skaggs is developing multiple small molecule therapies to treat high unmet needs, including regenerating tissue to reverse osteoarthritis, lung fibrosis, cardiac damage after a heart attack, loss of cells responsible for vision, and damage to skin from radiation and burns. Two of these therapies have reached phase 1 clinical trials, and multiple are following in the pipeline. Since many of these targets are conserved across tissues, learnings from advancing one therapy can be adapted to accelerate therapies in many diseases. As regenerative medicine has long relied on costly cell and gene therapies, this platform has the potential to revolutionize the field and provide accessible regenerative therapies for many of the world's most costly and devastating diseases.

References:

News, media and select publications: <https://calibr.scripps.edu/news-media/>

Clinical trials (NCT included, if available):

- NCT04077021: CCW702, bispecific antibody to treat metastatic prostate cancer

- used long-acting platform (antibody fusion strategy)
- NCT04450069: CLBR001 + SWI019, a switchable CAR-T cell therapy with a biologic \"switch\" targeting B-cell lymphoma cells (SWI019)
- Used sCAR-T platform
- NCT06878248: CLBR001 + ABBV461, a sCAR-T therapy with a biologic switch targeting metastatic breast cancer cells (ABBV461)
- Used sCAR-T platform
- NCT06913608: CLBR001 + SWI019, a sCAR-T therapy to treat autoimmune diseases
- Used sCAR-T platform
- CLF065, long-acting GLP2 to regenerate colonic epithelium in IBD
- Used long-acting platform (peptide stapling strategy)
- Preparation for 2 phase 2 clinical trials underway (pouchitis and EED)
- NCT03133676: KA34, a small molecule therapy to regenerate cartilage in patients with osteoarthritis
- Part of small molecule regenerative therapy pipeline
- CMR316, a small molecule inhalable therapy for regenerating lung epithelium after damage (CTA approval as trial ongoing in Germany)
- Part of small molecule regenerative therapy pipeline
- NCT05950906: PDM608, a long-acting GM-CSF biologic to treat neurodegenerative diseases such as Parkinson's and Alzheimer's diseases
- Used long-acting platform (protein fusion strategy)
- CMZ371, a peptide-stapled therapy for treating obesity and related metabolic disorders
- Used long-acting platform (peptide stapling)
- Subcutaneous IND accepted, oral IND in-progress
- NCT05475821: CMX990, Mpro inhibitor to treat SARS-CoV-2
- Initial hit identified in ReFRAME screen
- CLZ629 (GS-1614), a long-acting injectable to treat HIV infection
- Used long-acting injectable platform (formulation/depot strategy)
- NCT06558643: CBE161 (MMV371), a long-acting version of malaria therapy atovaquone to improve compliance in low- and middle-income countries
- Used long-acting platform (prodrug strategy)
- NCT06707142: CLB073 (TBD11), a novel therapy to enhance the efficacy of a current tuberculosis treatment regimen, reducing treatment duration from 6-9 months to <3.

Here is a list of select publications that exemplify our expertise in the drug discovery field and highlight our ability to accelerate development of therapies to the clinic.

- PMID: 39198974. \"Synthesis at the interface of chemistry and biology\" by Calibr-Skaggs CEO Pete Schultz describes how his work shaped his vision for establishing Calibr-Skaggs as a translational drug accelerator.
- PMID: 30282735. This publication describes the ReFRAME library and provides an example of its application in identifying treatments for cryptosporidiosis. The ReFRAME library has resulted in >150 publications by researchers around the world.
- PMID: 38335279. This paper describes CMX990 development. CMX990 is a

SARS-CoV-2 therapy whose development illustrates how the ReFRAME library and our experienced drug development team can accelerate therapies from discovery to clinical trials in less than 10 months. Description of the ReFRAME screening process for COVID-19 therapies is described in more detail here: PMID: 34083527.

- PMID: 39034055. "Discovery of novel anti-infective agents" discusses identification medicinal chemistry processes performed at Calibr-Skaggs to identify and develop therapies for diseases impacting global health that do not have a commercial benefit. This work has led to multiple clinical trials over the past decade and is exemplary of our vision to improve human health for all.

- PMID: 38598345. This paper discusses development of CMR316-a regenerative lung therapy in an ongoing phase 1 clinical trial in Germany in healthy volunteers and patients with interstitial pulmonary fibrosis (IPF)-from ReFRAME screen to determining mechanism of action.

- PMID: 37083395. "Perspectives on Schistosomiasis Drug Discovery..." discusses challenges and potential solutions to treating Schistosomiasis. This workshop included experts in Schistosomiasis drug discovery and clinical application of therapies, such as experts from the University of Dundee Drug Discovery Unit, Wellcome Trust, and Case McNamara representing Calibr-Skaggs.

- PMID: 33723431. "YAP-dependent proliferation by a small molecule targeting Annexin A2" describes discovery and development of a small molecule that activates a stem cell-like pathway in cells to promote proliferation. This discovery from Scripps Researchers has led to drug development programs at Calibr-Skaggs for skin (PMID: 37399395), heart (program in IND-enabling studies), and eye regeneration applications. This discovery led to a potentially paradigm-shifting approach to regenerative medicine-simplifying regenerative therapy by using locally applied small molecule to stimulate stem cell-like programs instead of using exogenous stem cells or gene therapies.

- PMID: 34380625. This article discusses development of a semisynthetic bispecific antibody to treat prostate cancer. This therapy was developed using an antibody fusion strategy-which is part of our long-acting platform-and was advanced to phase 1 clinical trials to treat metastatic prostate cancer.